Latest Safety News

SenSen Networks has successfully completed a key contract with Montréal’s Agence de mobilité durable, driving record full-year revenue growth exceeding 20%. The company anticipates strong cash collections into FY26, underscoring its expanding global footprint in AI-driven urban management.

Gibb River Diamonds advances key permits for its Edjudina Gold Project, aiming to begin mining at the Neta Prospect by August 2025 with minimal financial risk.

Actinogen Medical has enrolled its 100th participant in the XanaMIA phase 2b/3 Alzheimer’s trial, setting the stage for a critical interim analysis in January 2026 and final results by year-end.

Dimerix Limited has received a significant milestone payment from its Japanese partner FUSO Pharmaceutical, marking progress in the Phase 3 clinical trial of DMX-200 for kidney disease. This payment underscores the growing momentum behind Dimerix’s global licensing strategy.

LTR Pharma has successfully completed the extractables study for its intranasal erectile dysfunction spray SPONTAN, confirming safety compliance and initiating the next phase of leachables testing to support FDA approval.

WA1 Resources has announced a substantial upgrade to its Luni niobium deposit with a significant Indicated Mineral Resource Estimate and successful ferroniobium production testwork, positioning the West Arunta Project as a key player in the critical minerals sector.

Aquirian Limited has secured $5 million in fresh capital to upgrade its Wubin emulsion facility and accelerate commercialization of its innovative Collar Keeper® technology, alongside a new $1.5 million tolling contract.

Finder Energy has opened a new office in Dili to support its KTJ oil fields project, signalling a strategic push to embed local operations and partnerships in Timor-Leste.

Oceania Healthcare’s CEO delivered a confident first AGM address highlighting robust sales growth, operational efficiencies, and a refreshed strategic vision focused on care quality and sustainability.

Oceania Healthcare has modernized its property portfolio and updated its dividend policy to align with a new strategic direction under CEO Suzanne Dvorak, aiming to meet New Zealand's growing aged care demand.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.

PYC Therapeutics has announced promising pre-clinical results for its RNA-based drug candidate PYC-002, targeting the genetic root of Phelan-McDermid Syndrome, with clinical trials expected to begin in 2026.